Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Hot Stocks Free for All ! » GOVX - Promising AIDS Vaccine In The Works

 - UBBFriend: Email this page to someone!    
Author Topic: GOVX - Promising AIDS Vaccine In The Works
Wit
Member


Icon 14 posted      Profile for Wit     Send New Private Message       Edit/Delete Post   Reply With Quote 
This is BIG, IMO .

" Could Be A Very Promising Long Term Play "

Geovax Labs Inc. GOVX.OB

AIDS Vaccine Nearing Reality at Emory (GOVX.OB)


http://www.11alive.com/news/article_news.aspx?storyid=93439
http://www.11alive.com/video/player.aspx?aid=68340&bw=


Keith Whitney reports


Emory University researchers working on a vaccine for the AIDS virus
BTW: (Emory University owns 31% of the O/S.)

Web Editor: Keith Whitney
Last Modified: 3/8/2007 7:49:17 AM

The world could have a new vaccine designed to kill the AIDS virus in as little as three to four years according to an Atlanta-based group working on the vaccine.

It is a scientific advance that could save tens of millions of lives , and it is being developed on the campus of Emory University.

The work has been going on quietly for the last 15 years .
But now it appears headed for the bell lap in the race to prevent the disease.

And the Atlanta-based group may be way ahead of the rest of the world.

The GeoVax lab at Emory is smaller than many garages. And yet the small modular building may be where the battle to end the reign of one the world's biggest killers could be won with a vaccine to prevent AIDS.

"We're getting results back that indicate we're getting very strong immune responses in these individuals these people who received our vaccine," said Don Hildebrand, the president and CEO of GeoVax Inc., the company spearheading the research in collaboration with Emory, the Centers for Disease Control, and the National Institutes of Health.

The vaccine uses a decoy virus with some of the genetic material of the aids virus but not enough for anyone to ever get the disease itself from the shot, according to Dr. Harriet Robinson, Ph. D., of the Emory Vaccine Center.

"It exposes your immune system to a pathogen like a virus or bacteria so before you've seen it you set up memory cells,” Dr. Robinson said, “and then these memory cells mobilize should you get the actual infection."

The test trials have been so successful that the vaccine is now more than a year ahead of schedule.

"Actually another two trials are starting later this year using different combinations of our vaccine and different administration programs,” said GeoVax CEO Hildebrand. “And following that presuming everything goes well we'll be starting a phase two program at the end of the year."

The vaccine works using a one-two pharmaceutical punch to prime the body then kill the virus.

“It raises both antibodies that can block the virus and it raises white blood cells called t cells that can kill the virus infected cells,” said Dr. Robinson. “So it really has two methods of controlling an HIV/AIDS infection once it enters the body."

The vaccine’s success with the simian AIDS virus has been nothing short of remarkable.
Not only did the vaccine prevent the infection, it kept it under control for the monkeys that already had it, putting it in a kind of remission.

Researchers believe the same benefits await human subjects.

Website
www.geovax.com
Click on: News Room/Corporate News/ Media Coverage.

VIDEO:
http://www.firstcoastnews.com/video/player.aspx?aid=93235&bw=

--------------------
~You aren't wealthy until you have something money can't buy.~

Posts: 3070 | From: CT | Registered: Apr 2006  |  IP: Logged | Report this post to a Moderator
Wit
Member


Icon 1 posted      Profile for Wit     Send New Private Message       Edit/Delete Post   Reply With Quote 
AS was: 850,000,000 On 6/29/2006
OS was: 708,326,669 On 11/11/2006
(Emory University owns 31% of the O/S.)


GeoVax Labs, Inc.
1256 Briarcliff Road N.E
Emtech Bio Suite 500
Atlanta, GA 30306
United States

Phone: 404-727-0971
Andrew J. Kandalepas, CEO

Management

Andrew J Kandalepas SVP/VCB
Donald G Hildebrand PR/CEO/CB/FND
Mark W. Reynolds CFO/SEC


SIC Number: 2834
Fiscal Year End: 12-31
Industry: Drugs
Transfer Agent: American Stock Transfer & Trust Company
CIK: 832489

--------------------
~You aren't wealthy until you have something money can't buy.~

Posts: 3070 | From: CT | Registered: Apr 2006  |  IP: Logged | Report this post to a Moderator
trade04
Member


Rate Member
Icon 1 posted      Profile for trade04     Send New Private Message       Edit/Delete Post   Reply With Quote 
up big id like to see a pull back or a .35-.45 botttom before i jump in. what i dont get is that the last news was in early februar
Posts: 3086 | From: miami | Registered: Nov 2005  |  IP: Logged | Report this post to a Moderator
Wit
Member


Icon 1 posted      Profile for Wit     Send New Private Message       Edit/Delete Post   Reply With Quote 
Had More Recent News :

The article I posted above March 12, 2007 From News Channel 11.

http://www.11alive.com/news/article_news.aspx?storyid=93439


Also heard it was on CNN, haven't found that yet, will post when I do.


I would definitely wait for a pull back. It's up big now. JMO

--------------------
~You aren't wealthy until you have something money can't buy.~

Posts: 3070 | From: CT | Registered: Apr 2006  |  IP: Logged | Report this post to a Moderator
J_U_ICE
Member


Member Rated:
4
Icon 1 posted      Profile for J_U_ICE     Send New Private Message       Edit/Delete Post   Reply With Quote 
U.S. Government Awards $15 Million Grant to GeoVax Labs' HIV/AIDS Vaccine Program


ATLANTA, Sept. 26 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based biotechnology company, announced receipt of an estimated $15,000,000 Integrated Preclinical/Clinical AIDS Vaccine Development [IPCAVD] Grant to support its HIV/AIDS vaccine program.

This large Grant was awarded by the National Institutes of Health-National Institute of Allergy & Infectious Disease [NIH-NIAID], an agency of the U.S. Government. Funding commences October 2007.

Only meritorious HIV/AIDS prevention vaccine candidates are considered to receive an IPCAVD award. Candidate companies are highly scrutinized and must supply substantial positive AIDS vaccine data to support their application. IPCAVD grants are awarded on a competitive basis and are designed to support later stage vaccine research, development and human trials.

GeoVax will utilize this funding to further its HIV/AIDS vaccine development, optimization, production and human clinical trial testing including Phase 2 human clinical trials planned for 2008.

Dr. Harriet Robinson, Chief Scientific Advisor for GeoVax, guided development of the IPCAVD proposal and will lead a major part of its related studies. Dr. Robinson stated, "This grant will allow GeoVax to move forward our AIDS vaccine evaluation program more efficiently and more rapidly."

"Our selection as a grant recipient is a validation of our vaccine technology, scientific program, success in human trials to date and future strategies," said GeoVax President/CEO, Don Hildebrand. "This $15 million in funding will support additional AIDS vaccine studies as well as expansion of our scientific team at GeoVax."

About GeoVax Labs, Inc. (http://www.geovax.com)

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 filed patent applications and issued patents.

GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating individuals prior to infection with the AIDS virus. In addition, GeoVax AIDS vaccines may be effective as therapeutics (treatment of people infected with AIDS virus). Studies evaluating these vaccines in already HIV/AIDS infected individuals are being planned.

GeoVax DNA and Recombinant MVA HIV/AIDS vaccines:
-- Use DNA vaccines to "prime" immune responses and MVA vaccines to
"boost" immune responses against the AIDS virus
-- Vaccinate against more than 50% of AIDS virus components and can not
cause AIDS
-- Protected 22 of 23 (96%) non-human primates for over 3 1/2 years
post-infection with an AIDS inducing virus. Five of six non-vaccinated
controls died of AIDS within the 1st year of infection. These trials
used a prototype SIV/HIV vaccine for the HIV vaccine that is being
advanced in human trials
-- Are manufactured & tested under GMP/GLP - EMEA (EU) and FDA guidelines
-- Satisfactorily completed earlier DNA HIV/AIDS vaccine Phase 1 human
trial
-- Are currently being tested in 4 Human Trials. Two started in 2006, two
in summer 2007
-- Have been demonstrated safe to date in human trials
-- Are demonstrating positive immune responses against HIV in majority of
vaccine recipients
-- Are in planning stage for a larger Phase 2 human trial in 2008


For further information, contact Don Hildebrand or Jennifer Nelms at (404) 727-0971 or visit http://www.geovax.com.

Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be determined to be safe for use in humans, GeoVax's vaccines will be effective in preventing AIDS in humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed, GeoVax can raise the required capital to complete development of its vaccines, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitations, risks detailed in the Company's Securities and Exchange Commission filings and report.

SOURCE GeoVax Labs, Inc.


CONTACT: Don Hildebrand or Jennifer Nelms, both of GeoVax Labs, Inc., +1-404-727-0971; or Media, Tim Grace, +1-312-640-6667, or Phil Nourie, +1-212-827-3760, both of Financial Relations Board, for GeoVax Labs, Inc.
Web site: http://www.geovax.com


--------------------------------------------------------------------------------

Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Copyright © 1996-2005 PR Newswire Association LLC. All Rights Reserved.
A United Business Media company.

--------------------
The difference between genius and stupidity is that genius has its limits

Posts: 10204 | From: NYC | Registered: Mar 2006  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share